POSCPositron Corp.

About Positron Corp. (POSC)

Positron Corp. (POSC) is a Medical Devices company headquartered in Niagara Falls, NY, United States whose shares trade over-the-counter on the Pink tier.

Positron Corporation is a medical technology company that co-develops, manufactures, and sells state-of-the-art PET and PET-CT molecular imaging systems and clinical services to nuclear medicine healthcare providers throughout North America. Positron specializes in the field of cardiac PET imaging, the gold standard in nuclear cardiac diagnostics. Positron's innovative PET technology, clinical services and practice solutions enable healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes through providing superior cost-effective medicine. Positron has the exclusive North American distribution rights for the NeuSight PET-CT 3D 64 Slice scanner and ownership of the NeuSight FDA 510(k). Positron has also jointly developed a new Affinity PET-CT 4D 64 Slice system which it will manufacture, sell, service as well as provide clinical services and full support over the lifetime of the system. Positron's expansion to PET-CT was key to the Company's future in multiple imaging disciplines, likely setting Positron on a path for exponential growth with the NeuSight and Affinity PET-CT systems. Positron's PET-CT systems enable the Company to meet the new demands of the nuclear cardiology community and gives Positron the tools to enter and thrive in the oncology segment of the nuclear imaging market with what the Company's believes is the best product at the best price with the ability to service all healthcare providers.

Products and services

Positron's Attrius® PET and newly launched NeuSight PET-CT imaging systems and distinct market position are substantial advantages unique to Positron and will facilitate the adoption of the cardiac PET modality and the growth of the nuclear imaging market. Positron will soon offer an additional PET-CT 4D molecular imaging device in the Affinity PET-CT 4D 64-Slice scanner. Positron’s PET-CT(s) enables nuclear cardiologists to utilize the full capabilities of molecular imaging and nuclear medicine has to offer. Positron’s new NeuSight PET-CT (3D) and future Affinity PET-CT 4D systems enable the Company to enter the oncology imaging arena and meet the needs of the high-demand and vast oncology diagnostics marketplace. New advancements in PET imaging allow for the identification of coronary flow reserve, a measurement that detects the blood flow differences between rest and stress through the coronary arteries. This information, combined with the perfusion data, can help clinicians determine whether patients will benefit from mechanical revascularization. Positron is dedicated to improving the diagnostic process in oncology, neurology, and cardiology. Our scanners are built with versatility in mind so you can image new indications as they are approved for clinical application and reimbursement.

POSC key facts

Ticker symbol

POSC

Market tier

Pink

Sector

Healthcare

Industry

Medical Devices

Headquarters

Niagara Falls, NY, United States

Country of incorporation

US

Year of incorporation

1983

Employees

10

Estimated market cap

$42.26M (as of Apr 9, 2025)

Shares outstanding

31,305,008

Reporting standard

Alternative Reporting Standard

Audit status

Unaudited

Fiscal year end

12/31

Latest filing

Annual Report (Dec 31, 2024)

Positron Corp. leadership

• Adel Abdullah — President
• Aaron Hargrave — Vice President
• Karen Barry — Administrator

Explore more: Medical Devices stocks · Healthcare sector · Pink stocks · OTC stocks starting with P